Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
MENLO PARK, Calif., May 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on May 8, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-239-9838 from the United States or 1-323-794-2551 internationally approximately 10 minutes before the start of the call. The passcode is 3450659.
A replay will be available through May 22, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 3450659.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
